Analyzing ObsEva (NASDAQ:OBSV) and Evofem Biosciences (NASDAQ:EVFM)

Earnings & Valuation

This table compares ObsEva and Evofem Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A
Evofem Biosciences	$11.39 million	0.10	$52.98 million	($0.06)	-0.15

Evofem Biosciences has higher revenue and earnings than ObsEva. Evofem Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ObsEva and Evofem Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Institutional & Insider Ownership

17.5% of ObsEva shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.34, indicating that its stock price is 234% less volatile than the S&P 500.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.